Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MEDICARE HOME I.V. PRICING DATABASE CONTRACT AWARDED TO FIRST DATABANK

Executive Summary

MEDICARE HOME I.V. PRICING DATABASE CONTRACT AWARDED TO FIRST DATABANK, the electronic services publishing division of Hearst Corp. First DataBank announced Aug. 18 that it has been chosen by the Health Care Financing Administration to "develop and maintain a prescription drug pricing database" for home intravenous and immunosuppressive drugs covered under the first phase of the new Medicare drug benefit. The contract does not include claims processing; that function will be handled by existing Medicare carriers. First DataBank's responsibilities "will involve calculating prices, adding new products, indicating which drugs are available from only one source or from several sources, and assigning Orange Book codes to drugs with two or more therapeutically equivalent products available," the firm said. Medicare coverage for home I.V. and immunosuppressive drugs begins Jan. 1, 1990. The contract with First DataBank is a one-year contract for calendar year 1990. Because it covers data management for only two categories of treatments, the contract is a relatively small one in the overall context of the Medicare outpatient drug benefit. The contract is worth only $ 22,680. However, First DataBank plans to enter a bid for the claims processing contracts that will be awarded for the full outpatient drug benefit, which is scheduled to go into effect beginning in January 1991. Headquartered in San Bruno, Calif., First DataBank currently operates a broad prescription drug computerized database that includes economic and clinical information. The data file "contains over 140,000 NDC numbers which represent every drug approved by the Food and Drug Administration," First DataBank noted. The firm said that, in addition to Medicaid programs, the data file is used by "more than 40" private third party administrators including PCS, PAID, Rx, Michigan Blue Cross and Metropolitan as well as by "more than 2,500" hospitals including Hospital Corporation of America, Kaiser Foundation and Humana, and 25,000 pharmacies. First DataBank also publishes The Blue Book, a reference of drug average wholesale prices that has been used by HCFA in the Medicaid program. The contract will be under the direction of First DataBank General Manager Joseph Hirschmann. The pharmacy aspects of the project will be handled by Marty Lockwood, the company's professional services manager. Lockwood will be responsible for preparing the initial home I.V. and immunosuppressive drug selection criteria in conjunction with HCFA. She will also handle: "direction of data collection from the published national compendium; analysis and review of mediam AWP algorithms and program output; design, implementation and testing of the database; ]and[ design, implementation and testing of file update algorithms."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS016143

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel